NEW OPPORTUNITIES IN THE TREATMENT OF PATIENTS WITH DYSCIRCULATORY ENCEPHALOPATHY, CAUSED BY METABOLIC SYNDROME
T. Mishchenko, V. Derevetska, V. Mishchenko, K. Kharina
Summary
The article presents the results of a clinical study examination the efficacy and tolerability of the use of fixed phytocomposition Memostim (Ananta Medicare, United Kingdom) in patients with dyscirculatory encephalopathy (DE) stage II, caused by metabolic syndrome. The phytocomposition was given to the Substitutes in 30 patients with DE stage II with metabolic syndrome (main study group) within 3 months. Patients received 1 capsule 2 times a day during the first month, then 1 capsule 1 time per day for two months.
The comparison group consisted of 30 patients with DE stage II with a metabolic syndrome, where phytocomposition Memostim was not add to the standard course of therapy. Efficiency and safety of phytocomposition of the Memostim were assessed on the basis of clinical neurological, psychodiagnostical, biochemical, immunoenzymatic, and statistical methods. After three months of treatment, a significant decrease in the frequency and intensity of clinical and neurological manifestations of the disease was observed, and a positive dynamics in the neurocognitive sphere, psycho-emotional state of patients was noted. The concentration of the human nerve growth factor (NGF-β) increased for 67 %, which indicated the recovery of neuroplasticity.
Keywords: dyscirculatory encephalopathy, metabolic syndrome, cognitive impairment, phytocomposition Memostim, treatment
Introduction
According to the World Health Organization, the problem of cerebrovascular disease (CVD) is becoming the most pressing problem of clinical medicine, due to the aging of the world's population and increasing prevalence of CVD risk factors in the population [1]. As in other countries, this problem is relevant in Ukraine. Over the past 10 years, the number of patients with CVD in our country has doubled: currently the incidence exceeds 8,200 cases per 100,000 population, due to an increase in the proportion of both strokes and chronic forms of cerebral disorders.
Today more than 2.5 million people suffer from CVD of varying severity in Ukraine. Almost 100,000 new stroke cases occur in the country every year. In the structure of CVD, 4-5% are acute conditions, the rest – 95-96% – chronic cerebrovascular disorders [2].
To define chronic cerebrovascular disorders in clinical practice in our country, the term with the nosological meaning "dyscirculatory encephalopathy" (DE) is used.
Dyscirculatory encephalopathy is a slowly progressive diffuse and focal lesion of the brain due to chronic deterioration of cerebral circulatory disorders. Although the term originated in the 1960s, due to its clinical significance, it is still used today. Other similar definitions that have a syndromic or nosological content are chronic cerebral insufficiency, chronic cerebrovascular insufficiency, slowly progressive cerebral insufficiency, cerebrovascular disease, coronary heart disease, etc. In some countries, the term "dyscirculatory encephalopathy" is used instead of "vascular dementia", "vascular cognitive impairment".
As for the International Classification of Diseases of the 10th revision (ICD-10), the diagnoses - analogues of DE are as follows: 167.2 - cerebral atherosclerosis, 167.4 - hypertensive encephalopathy, 167.9 - unspecified vascular diseases.